Gritstone bio has received a contract valued at up to $433m from the US Biomedical Advanced Research and Development Authority (BARDA) for a Phase IIb clinical trial of its self-amplifying mRNA (samRNA) Covid-19 vaccine candidate.
The vaccine candidate comprises spike plus other viral targets to offer protection against the disease.
Go deeper with GlobalData
Discover B2B Marketing That Performs
Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.
This agreement is part of the US Department of Health and Human Services Project NextGen programme, intended to progress various new therapies and vaccines for Covid-19
As part of the new contract, Gritstone bio will launch a randomised, double-blinded Phase IIb clinical trial enrolling a total of 10,000 subjects.
The trial will analyse the safety, immunogenicity and efficacy of the vaccine candidate against a currently approved Covid-19 vaccine.
Preparations for the study are currently progressing, with BARDA completely financing its execution.
US Tariffs are shifting - will you react or anticipate?
Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.
By GlobalDataDubbed CORAL-BARDA, the Phase IIb study is expected to commence in the first quarter of 2024.
For conducting the study in the US, Gritstone bio will partner with the Covid-19 Prevention Network.
The company published interim data from the Phase I study of the Covid-19 vaccine (CORAL-BOOST) in June 2023.
Gritstone bio co-founder, president and CEO Andrew Allen said: “Not only does this contract supply the necessary resources to advance the development of CORAL, but it also signifies the trust and confidence the US Government has placed in our novel vaccine approach.
“Across multiple Phase I studies, our samRNA vaccine, which incorporates both Spike and other viral targets (Spike plus), has demonstrated induction of potent immune responses with potential to drive broad and durable clinical protection – this potential will now be tested in a randomised setting.”
Cell & Gene therapy coverage on Clinical Trials Arena is supported by Cytiva.
Editorial content is independently produced and follows the highest standards of journalistic integrity. Topic sponsors are not involved in the creation of editorial content.
